Investors: Brian Blanchett +1.858.291.6421 ir@illumina.com Media: Christine Douglass pr@illumina.com Illumina Reports Financial Results for First Quarter of Fiscal Year 2025 | | | | GAAP | | | | Non-GAAP (a) | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | Dollars in millions, except per share amounts | | Q1 2025 | | Q1 2024 | | Q1 2025 | | Q1 2024 | | Revenue (b) | $ | 1,041 | $ | 1,056 | $ | 1,041 | $ | 1,056 | | Gross margin (c) | | 65.6 % | | 65.7 % | | 67.4 % | | 67.1 % | | Research and de ...

Wall Street analysts forecast that Illumina (ILMN) will report quarterly earnings of $0.96 per share in its upcoming release, pointing to a year-over-year increase of 966.7%. It is anticipated that revenues will amount to $1.04 billion, exhibiting a decline of 3.5% compared to the year-ago quarter.The consensus EPS estimate for the quarter has undergone a downward revision of 0.6% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed th ...

First real-world dataset with integrated clinical and multiomic insights from 25,000 patients treated with GLP-1 therapiesDataset will advance development of GLP-1 therapies in new indications and accelerate discovery of novel drug targets in patients who are unresponsive to therapiesSAN DIEGO, May 1, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), and Ovation.io, Inc., an organization dedicated to building best-in-class multiomics datasets, today announced the development of the largest commercially av ...

Collaboration accelerates insights on clinical benefits of molecular profiling across all major categories of diseaseSAN DIEGO and CHICAGO, April 15, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel evidence generation. The collaboration will combine leading Illumin ...

SAN DIEGO, April 10, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2025 following the close of market on Thursday, May 8, 2025. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call DetailsThe conferen ...

Company Overview - Illumina provides sequencing and array-based solutions for genetic and genomic analysis, enabling the adoption of genomic solutions in research and clinical settings [1] - The company's DNA sequencing technology is based on reversible terminator-based sequencing chemistry, known as sequencing by synthesis biochemistry [1] - Illumina's BeadArray technology combines microscopic beads and a substrate to produce arrays that can perform multiple assays simultaneously [1] Recent Developments - On March 25, Illumina announced that Keith Meister will join the board on March 28, and Dr. Scott Gottlieb has been elected as the non-executive chair of the board [3] - Stephen MacMillan will retire as a director, having joined the board in June 2023 [3] Financial Performance - Illumina's revenue surged by approximately 40% from $3.2 billion in 2020 to $4.5 billion in 2021, with EBITDA increasing from $800 million to $1.1 billion during the same period [4] - Current revenue stands at $4.3 billion, with EBITDA at $900 million, and the stock closed at $80.00 [4] Challenges and Setbacks - Post-pandemic, demand for sequencing machines declined, primarily due to the costly spin-out and reacquisition of its Grail business, which was acquired for $8 billion [5] - The acquisition faced regulatory challenges, including a block from the European Commission and a significant fine [5] - Illumina's market valuation has dropped from $70 billion to less than $13 billion due to these challenges and geopolitical setbacks in Russia and China [5] Market Position and Strategy - Illumina controls over 80% of the global gene-sequencing market and has an installed base of more than 20,000 machines [6] - The company operates under a razor-and-blade business model, with machine margins around 30% and consumable sales margins at approximately 80% [6] - The transition to a new generation of sequencing technology, NovaSeq X, is expected to drive long-term growth but may create short-term revenue pressure [6] Board Composition and Future Outlook - Keith Meister's addition to the board is seen as a positive move, given his experience and past success in creating value as a director in various companies [7] - Corvex Management, founded by Meister, is a concentrated hedge fund that uses activism as a tool, indicating a potential for strategic influence on Illumina's direction [2][7]

Group 1 - Illumina, Inc. (NASDAQ: ILMN) is rated with a BUY rating, indicating a belief that the market has overreacted to the financial losses due to the GRAIL divestiture [1] - The financial losses reported by Illumina are seen as temporary and not reflective of the company's long-term potential [1] - The analyst has a background in economics and statistics, with experience in analyzing agricultural commodities and managing trading teams [1] Group 2 - The analyst's approach to generating buy and sell recommendations is based on financial statements, regulations, and macroeconomic variables [1]

Core Insights - Illumina, Inc. announced changes to its Board of Directors, with Scott Gottlieb elected as non-executive Chair and Keith Meister joining the board, while Stephen MacMillan will retire [1][2] Group 1: Board Changes - Scott Gottlieb, MD, has been elected as the non-executive Chair of Illumina's Board, having served since 2020 [1][2] - Keith Meister, founder and Chief Investment Officer of Corvex Management, will join the Board on March 28, 2025 [1] - Stephen MacMillan, who joined the board in June 2023, has decided to retire in preparation for the upcoming annual meeting of shareholders [1] Group 2: Statements from Board Members - Dr. Gottlieb expressed gratitude towards MacMillan for his contributions and emphasized the importance of advancing the company's mission and driving profitable growth [2] - MacMillan reflected positively on Illumina's achievements in genomics and expressed confidence in the board and management team [2] - Meister highlighted Illumina's strategy to expand its role in genomics and expressed confidence in the company's ability to accelerate revenue growth [2] Group 3: Background of Board Members - Scott Gottlieb served as the 23rd Commissioner of the U.S. FDA and is currently a Partner at New Enterprise Associates, with a strong background in public health and policy [3] - Keith Meister founded Corvex Management in 2010 and serves on multiple boards, bringing extensive investment experience to Illumina [4] Group 4: Company Overview - Illumina is a global leader in DNA sequencing and array-based technologies, focusing on innovation to improve human health [5] - The company's products are utilized across various applications, including life sciences, oncology, reproductive health, and agriculture [5]

Company Developments - Illumina, Inc. and Nashville Biosciences announced the sequencing of 250,000 whole genomes for the Alliance for Genomic Discovery initiative, which aims to accelerate drug target discovery and therapeutic research [1][2] - The AGD initiative, co-launched in 2022, is a multiyear project focused on developing a clinical genomic resource [2] - Illumina's AGD dataset is being shared with eight biopharma members, including AbbVie, Amgen, and AstraZeneca, using Illumina Connected Analytics as a research tool [5][6] Financial Performance - Following the announcement, Illumina's stock price increased by 3.2%, closing at $87.66 [3] - The company has a market capitalization of $13.89 billion and an earnings yield of 5.1%, significantly higher than the industry's -33.6% yield [4] - Illumina has achieved an earnings beat of 106.1% on average over the trailing four quarters [4] Industry Insights - The global genomics market was valued at $32.65 billion in 2023 and is projected to grow at a compound annual growth rate of 16.5% by 2030, driven by demand for gene therapy and personalized medicine [8] - The AGD initiative is expected to provide a dynamic research platform, yielding novel target discoveries in various diseases [7] Recent Innovations - Illumina recently unveiled a comprehensive portfolio of omics solutions and sequencing applications, enhancing its capabilities in genomics and related fields [10]

Core Insights - Illumina Inc. and Nashville Biosciences have successfully sequenced 250,000 whole genomes for the Alliance for Genomic Discovery, creating one of the largest clinical genomic datasets globally [1][2][11] - The AGD initiative aims to accelerate drug target discovery and therapeutic research, leveraging insights from the dataset [1][4][6] Group 1: Dataset and Achievements - The AGD dataset is a significant resource for biopharma members, providing de-identified DNA samples and integrated clinical phenotype data [4][12] - The dataset's diversity and depth have already led to novel target discoveries in various disease areas, including autoimmune and metabolic diseases [6][5] - The rapid completion of sequencing in just two years highlights the collaborative efforts of AGD and its member organizations [10][9] Group 2: Future Directions - The next phase of the AGD will focus on adding multiomic layers to enhance the dataset's breadth and depth [7][8] - There is strong interest from AGD members in exploring additional omics modalities, such as proteomics, to further understand disease mechanisms [8][6] - Illumina plans to expand its portfolio of multiomic capabilities, aiming to provide a comprehensive range of omics solutions and sequencing applications [8][14] Group 3: Industry Context - The AGD initiative was launched in 2022 and includes major biopharma companies like AbbVie, Amgen, and Merck, which utilize the dataset for identifying disease associations [11][12] - A study published in Nature indicates that drugs with a genetic basis are 2.6 times more likely to succeed, underscoring the importance of genetic evidence in drug discovery [5]